Circulation:他汀或可抑制高血压和糖尿病患者醛固酮的分泌

2015-10-22 小田 译 医学论坛网

他汀类药物确实可减少心血管死亡率,并且似乎这种益处是独立于降脂治疗特性的。多国学者近期评估了他汀类药物是否可调节醛固酮的分泌,后者可导致心血管疾病。结果表明,高血压和糖尿病患者应用他汀与醛固酮分泌减少有关,这一影响似乎在使用亲脂性他汀和较大剂量应用者中最为明显。相关论文近期发表于《循环》(Circulation)杂志。 研究者们对两项干预试验中的受试者检测了肾上腺激素。在第一项试验的高血

他汀类药物确实可减少心血管死亡率,并且似乎这种益处是独立于降脂治疗特性的。多国学者近期评估了他汀类药物是否可调节醛固酮的分泌,后者可导致心血管疾病。结果表明,高血压和糖尿病患者应用他汀与醛固酮分泌减少有关,这一影响似乎在使用亲脂性他汀和较大剂量应用者中最为明显。相关论文近期发表于《循环》(Circulation)杂志。

研究者们对两项干预试验中的受试者检测了肾上腺激素。在第一项试验的高血压受试者中,分析其基线以及高钠和低钠饮食后血管紧张素-II刺激后的醛固酮水平(1122个观察对象,15%接受为期3个月的他汀类药物治疗)。结果显示,在校正模型中,他汀使用者的醛固酮水平低了33%(P< 0.001)。皮质醇水平不受他汀影响。在次要分析中,亲脂性他汀和较大剂量他汀使用者的醛固酮水平最低。他汀使用者的血压较低,且血压的盐敏感性减少(P=0.001)。

在第二项研究中,研究者们检测了高盐饮食糖尿病患者血管紧张素-II刺激后的醛固酮水平(143个观察对象,79%是他汀类药物使用者)。研究结果再次证明他汀使用者的醛固酮水平较低(低了26%,P=0.006),尤其是那些用亲脂性他汀者。

大鼠肾上腺球状带细胞的体外研究也再次验证了亲脂性他汀可强烈抑制醛固酮,而不抑制皮质酮。

原文出处:

Rene Baudrand1,Luminita H. Pojoga2,et al.Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects .CIRCULATION.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1682223, encodeId=8d4e1682223ec, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Nov 16 05:23:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40662, encodeId=7cfc40662d8, content=最新发现,好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Sat Oct 24 17:47:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379205, encodeId=70c713e920573, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 24 00:23:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473905, encodeId=f7b714e3905df, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Oct 24 00:23:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40465, encodeId=d7f5404656c, content=找找同行,一起做个对照,等结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4361657743, createdName=1dde076cm77(暂无匿称), createdTime=Fri Oct 23 15:29:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40253, encodeId=66fb40253e4, content=看看先, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Oct 22 12:54:00 CST 2015, time=2015-10-22, status=1, ipAttribution=)]
    2015-11-16 gwc392
  2. [GetPortalCommentsPageByObjectIdResponse(id=1682223, encodeId=8d4e1682223ec, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Nov 16 05:23:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40662, encodeId=7cfc40662d8, content=最新发现,好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Sat Oct 24 17:47:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379205, encodeId=70c713e920573, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 24 00:23:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473905, encodeId=f7b714e3905df, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Oct 24 00:23:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40465, encodeId=d7f5404656c, content=找找同行,一起做个对照,等结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4361657743, createdName=1dde076cm77(暂无匿称), createdTime=Fri Oct 23 15:29:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40253, encodeId=66fb40253e4, content=看看先, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Oct 22 12:54:00 CST 2015, time=2015-10-22, status=1, ipAttribution=)]
    2015-10-24 nizongzan

    最新发现,好好学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1682223, encodeId=8d4e1682223ec, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Nov 16 05:23:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40662, encodeId=7cfc40662d8, content=最新发现,好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Sat Oct 24 17:47:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379205, encodeId=70c713e920573, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 24 00:23:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473905, encodeId=f7b714e3905df, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Oct 24 00:23:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40465, encodeId=d7f5404656c, content=找找同行,一起做个对照,等结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4361657743, createdName=1dde076cm77(暂无匿称), createdTime=Fri Oct 23 15:29:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40253, encodeId=66fb40253e4, content=看看先, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Oct 22 12:54:00 CST 2015, time=2015-10-22, status=1, ipAttribution=)]
    2015-10-24 cmsvly
  4. [GetPortalCommentsPageByObjectIdResponse(id=1682223, encodeId=8d4e1682223ec, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Nov 16 05:23:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40662, encodeId=7cfc40662d8, content=最新发现,好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Sat Oct 24 17:47:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379205, encodeId=70c713e920573, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 24 00:23:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473905, encodeId=f7b714e3905df, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Oct 24 00:23:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40465, encodeId=d7f5404656c, content=找找同行,一起做个对照,等结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4361657743, createdName=1dde076cm77(暂无匿称), createdTime=Fri Oct 23 15:29:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40253, encodeId=66fb40253e4, content=看看先, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Oct 22 12:54:00 CST 2015, time=2015-10-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1682223, encodeId=8d4e1682223ec, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Nov 16 05:23:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40662, encodeId=7cfc40662d8, content=最新发现,好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Sat Oct 24 17:47:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379205, encodeId=70c713e920573, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 24 00:23:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473905, encodeId=f7b714e3905df, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Oct 24 00:23:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40465, encodeId=d7f5404656c, content=找找同行,一起做个对照,等结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4361657743, createdName=1dde076cm77(暂无匿称), createdTime=Fri Oct 23 15:29:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40253, encodeId=66fb40253e4, content=看看先, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Oct 22 12:54:00 CST 2015, time=2015-10-22, status=1, ipAttribution=)]
    2015-10-23 1dde076cm77(暂无匿称)

    找找同行,一起做个对照,等结果

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1682223, encodeId=8d4e1682223ec, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Nov 16 05:23:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40662, encodeId=7cfc40662d8, content=最新发现,好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Sat Oct 24 17:47:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379205, encodeId=70c713e920573, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 24 00:23:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473905, encodeId=f7b714e3905df, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Oct 24 00:23:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40465, encodeId=d7f5404656c, content=找找同行,一起做个对照,等结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4361657743, createdName=1dde076cm77(暂无匿称), createdTime=Fri Oct 23 15:29:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40253, encodeId=66fb40253e4, content=看看先, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Thu Oct 22 12:54:00 CST 2015, time=2015-10-22, status=1, ipAttribution=)]
    2015-10-22 owlhealth

    看看先

    0

相关资讯

ACC/AHA胆固醇指南能更**和更有效识别适宜他汀治疗人群

2013年美国心脏病学会和美国心脏学会(ACC /AHA)胆固醇治疗指南已阐述了他汀类药物新的适用原则,但这部指南是否能够改善那些心血管事件高风险成人的识别力尚不清楚。因此,美国学者近期对比了2004年美国胆固醇教育计划成人治疗组第三次更新版的胆固醇检评估和治疗指南(以下简称ATP III指南)与2013年ACC/AHA胆固醇治疗指南(以下简称ACC/AHA指南)对心血管事件高风险成人的识别力进行

地中海饮食防治中年人心脑血管病 可与他汀相媲美

为了控制疾病风险,具有卒中或心脏病风险患者应采用地中海饮食,而不是一味的接受他汀治疗。这一观点正得到越来越多医学专家的认可。在最近发表的一篇声明中,众多专家一致呼吁患者健康饮食、积极运动、停止吸烟,这些生活干预方式与降脂药物治疗同样重要。另外包括英国卫生质量标准署(NICE)在内的医学团队应减少“药物治疗防控风险”的依赖性。参与该声明的专家认为,医生应为患者提供有关他汀治疗利弊的更多信息,并给出一

ESC2015:他汀治疗降低vWF抗原水平

2015欧洲心脏病学会年会(ESC2015)专题报道 背景 vWF抗原水平的增加与高危冠心病风险密切相关。他汀治疗对vWF抗原水平的影响尚无定论。 目的 评价他汀治疗对vWF抗原水平的影响。 方法 检索PUBMED、Cochrane Library、Scopus及EMBASE数据库中截至2015-1-31的随机对照研究,以评价他汀治疗对血浆vWF抗原水平的影

JAMA:他汀对心血管病一级预防 更经济高效

在用他汀类药物治疗动脉粥样硬化(ASCVD)成人患者方面,美国心脏病学会和美国心脏学会(ACC /AHA)胆固醇治疗指南有广泛的影响。近期,美国学者们对他汀用于心血管疾病一级预防的成本-效益进行了评估。 研究者们采用微观模型,包括美国人寿命、费用3%的折扣率和健康结局。在模型中,受试者为年龄在40至75岁之间接受他汀治疗并经历过ASCVD事件,以及根据ASCVD自然史和他汀治疗参数死于ASCVD

2015年《血脂异常老年人使用他汀类药物中国专家共识》解读

老年人是动脉粥样硬化性心血管疾病(ASCVD)的高危人群,是他汀类药物治疗的适宜人群。而出于对老年人应用他汀类药物是否获益及安全性的担忧,老年人他汀类药物的应用严重不足。2015年第5期《中华内科杂志》发表了《血脂异常老年人使用他汀类药物中国专家共识)》(以下简称“共识”)。本版共识是在2010年发表的《血脂异常老年人使用他汀类药物中国专家共识》的基础上,结合近年血脂异常治疗的进展,综合众多老

BMC Neurol:卒中前用他汀可减少卒中严重度并促进患者早期功能恢复

既往研究表明,卒中前他汀类药物治疗对缺血期和缺血损伤后神经恢复的神经保护具有双重影响。因此,韩国学者评估了卒中前应用他汀类药物对首次卒中严重度和早期临床转归的影响。 研究者分析了来自韩国12家医院8324例急性缺血性卒中患者的前瞻性数据。主要终点为美国国立卫生研究院卒中量表(NIHSS)评分下的首次卒中严重度。次要终点为出院时良好转归[改良Rankin量表(mRS)评分0-2分]和总